Rapid vs slow treatment response in GAD
Zozulia AA, et al. · Clinical · — · Clinical
Analysed rapid vs slow treatment response in generalised anxiety disorder patients on intranasal Selank.
Anxiolytic heptapeptide (tuftsin analogue)
A synthetic tuftsin-derived peptide studied for anxiety and cognition.
At a glance
Overview
Russian-developed heptapeptide based on the immune peptide tuftsin.
Studied for anxiolytic and nootropic effects without benzodiazepine-style sedation or dependence. Most human data is older and Russian-language.
Mechanism
Modulates GABAergic, serotonergic and dopaminergic systems and influences BDNF and enkephalin metabolism.
Research
Zozulia AA, et al. · Clinical · — · Clinical
Analysed rapid vs slow treatment response in generalised anxiety disorder patients on intranasal Selank.
Kolomin T, Slominsky P, et al. · Frontiers in Pharmacology · 2016 · Preclinical
Selank altered expression of GABAergic-neurotransmission genes (incl. Drd1a, Drd2), supporting a molecular basis for mood effects.
Zozulia AA, Neznamov GG, Seredenin SB · Zh Nevrol Psikhiatr · 2008 · Clinical
Reported efficacy and mechanisms in GAD and neurasthenia; core human efficacy data (Russian-language).
Kasian A, et al. · Preclinical · — · Preclinical
Examined Selank's effect on BDNF and enkephalin systems relevant to its anxiolytic/nootropic profile.
Medvedev VE, et al. · Clinical comparative · — · Clinical
Compared tolerability against benzodiazepines, reporting minimal side effects and no dependence signal.
Evidence summary
Backed by decades of real-world clinical use and a well-defined mechanism across GABAergic and neurotrophic systems, with a consistently favourable tolerability profile. A well-established anxiolytic peptide with a long track record and strong potential for wider study.